If You Invested $1,000 in Larimar Therapeutics Inc (LRMR)
This article analyzes the historical performance of investing $1,000 in Larimar Therapeutics Inc (LRMR) over 1, 5, and 10 years, detailing the returns and compound annual growth rates. It also provides an overview of Larimar Therapeutics, a clinical-stage biotechnology company focused on developing treatments for rare diseases, particularly Friedreich’s ataxia with its lead compound nomlabofusp. The piece covers regulatory interactions, clinical data highlights, safety profiles, and the company's financial strategies.
Here’s What Citi Thinks About Larimar Therapeutics (LRMR)
Citi analyst Samantha Semenkow maintained a Buy rating on Larimar Therapeutics (LRMR) with a $14 price target, citing optimism surrounding its lead drug Nomlabofusp for Friedreich’s ataxia. The bullish outlook is driven by upcoming catalysts including new clinical data and a planned rolling FDA submission. The analyst anticipates the drug will achieve a carrier-like state and show continued improvement with good safety results over a full year of data.
LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns
Shares of Larimar Therapeutics (LRMR) held steady despite recent weakness driven by drug safety concerns, as Wall Street analysts maintained bullish ratings. H.C. Wainwright initiated coverage with a 'Buy' rating and a $10 price target, citing the company's regulatory progress for nomlabofusp, which is expected to launch in 2027 with significant sales potential. Citi also recommended buying LRMR shares, and retail sentiment on Stocktwits remained "extremely bullish."
Price to book forward of Larimar Therapeutics, Inc. – LS:A2P5PP
This article provides financial information for Larimar Therapeutics, Inc. under the stock symbol LS:A2P5PP. It specifically highlights the "Price to book forward" metric. The content appears to be a financial data page from TradingView, indicating that the market is currently closed with no trades.
LRMR Assumed by HC Wainwright & Co. -- Rating Set to Buy
HC Wainwright & Co. has initiated coverage on Larimar Therapeutics (LRMR) with a Buy rating and a price target of $10.00, citing confidence in the company's potential despite its current low profitability and growth metrics. Larimar Therapeutics, a clinical-stage biotechnology company, is focused on developing treatments for rare diseases, particularly Friedreich's ataxia. The stock's current trading price of $3.205 suggests it may be undervalued based on the analyst's target, although a comprehensive valuation is limited by the unavailability of GF Value™ data.
Price to book forward of Larimar Therapeutics, Inc. – NASDAQ:LRMR
This page from TradingView displays the "Price to book forward" metric for Larimar Therapeutics, Inc. (NASDAQ: LRMR). The content indicates the company's financial overview within the health technology and biotechnology sectors. It also includes general disclaimers about market data and copyright information.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Pomerantz LLP is investigating potential securities fraud claims against Larimar Therapeutics, Inc. on behalf of its investors. The investigation stems from two significant drops in Larimar's stock price following announcements of clinical trial data for its drug nomlabofusp, where "positive" characterizations were overshadowed by disclosures of anaphylaxis in participants. The firm is inviting affected investors to contact them for a potential class action lawsuit.
Enterprise value to EBIT forward of Larimar Therapeutics, Inc. – LS:A2P5PP
This article provides access to the enterprise value to EBIT forward data for Larimar Therapeutics, Inc. (LS:A2P5PP) on the TradingView platform. It highlights that the market was closed at the time of access and no trades were recorded. The financial data is provided by ICE Data Services and FactSet, with SEC filings from Quartr.
LRMR Stock Dips As Traders Weigh Cash Runway And Volatility
Larimar Therapeutics Inc. (LRMR) stock fell by 15.16% due to concerns over clinical trial and regulatory updates, closing around $3.11 after an intraday high of $4.30. Despite a strong cash position of $178.5 million, the biotech firm is burning significant cash on R&D, making it a high-risk, high-reward investment. Traders are closely watching its consolidation within the $3.10-$3.70 range for potential breakouts.
Larimar says FDA can review nomlabofusp for accelerated approval
Larimar Therapeutics (LRMR) has submitted the first module of a rolling Biologics License Application (BLA) for accelerated FDA approval of nomlabofusp, a treatment for Friedreich’s ataxia. The FDA noted that existing data, including sustained increases in skin frataxin (FXN) levels and directional clinical improvements, appear sufficient for review, accepting FXN as a potential surrogate endpoint. Despite positive clinical and biomarker trends, the stock declined by 12.57% on the news, partially due to concerns over reported anaphylaxis events in the open-label study.
Larimar Stock Slides 15% Despite FDA Backing Rolling Submission For Rare Disease Drug
Larimar Therapeutics' stock fell by 15% despite the FDA backing a rolling Biologics License Application (BLA) submission for nomlabofusp, its rare disease drug for Friedreich's ataxia. The FDA indicated that existing data appears capable of supporting the BLA and agreed to consider frataxin as a novel surrogate endpoint. Long-term study data also showed a durable safety profile and directional improvements in clinical measures for treated patients.
Larimar Therapeutics, Inc.(NasdaqGM:LRMR) added to Russell Microcap Growth Benchmark Index
Larimar Therapeutics, Inc. (NasdaqGM:LRMR) has been added to the Russell Microcap Growth Benchmark Index. This news follows several other index-related adjustments for the company and other significant corporate updates, including filing the first module of its Biologics License Application (BLA) for nomlabofusp with the US FDA. Larimar Therapeutics is a clinical-stage biotechnology company focused on rare diseases, with its lead candidate nomlabofusp targeting Friedreich's ataxia.
Larimar Therapeutics submits first module of rolling BLA for nomlabofusp in Friedreich’s ataxia
Larimar Therapeutics has submitted the first module of a rolling Biologics License Application (BLA) to the FDA for accelerated approval of nomlabofusp, a treatment for Friedreich’s ataxia. The company expects to submit the remaining BLA modules in the second half of 2026. Open-label data indicates sustained increases in skin frataxin levels and directional clinical improvements, with a safety profile consistent with prior studies.
Larimar Therapeutics submits first module of rolling BLA after positive nomlabofusp open‑label data
Larimar Therapeutics has submitted the first module of a rolling Biologics License Application (BLA) for accelerated approval of nomlabofusp, citing positive long-term open-label data. The data indicates sustained increases in skin FXN and clinical improvements. The company anticipates submitting remaining modules in the second half of 2026, with a target launch in mid-2027 if approved.
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
Larimar Therapeutics announced the submission of the first module of its rolling Biologics License Application (BLA) for accelerated approval of nomlabofusp, a treatment for Friedreich’s ataxia. The company also reported positive long-term open-label study data, showing sustained increases in skin frataxin levels and directional improvements in clinical outcomes for patients treated with nomlabofusp. The FDA has confirmed the sufficiency of the data package to support accelerated approval based on skin frataxin as a potential novel surrogate endpoint.
LRMR Stock Slides As Traders Eye Cash Runway And Volatility
Larimar Therapeutics Inc. (LRMR) stock has dropped by 14.62% due to bearish sentiment surrounding its recent clinical developments. Despite concerns over profitability, the company maintains a strong cash position of approximately $178 million, providing a significant runway for operations. Traders are closely monitoring LRMR's volatile intraday action, characterized by sharp premarket gains followed by regular-session fades, highlighting its high-risk, high-reward biotech profile.
Larimar Therapeutics, Inc.(NasdaqGM: LRMR) added to Russell 2000 Growth Benchmark
Larimar Therapeutics, Inc. (NasdaqGM: LRMR) has been added to the Russell 2000 Growth Benchmark index. This inclusion highlights the company's growth trajectory within the biotechnology and medical research sector. The company is focused on developing treatments for rare diseases, with its lead product candidate, nomlabofusp, targeting Friedreich's ataxia.
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich's Ataxia
Larimar Therapeutics is hosting an investor event to discuss updates on its nomlabofusp program for Friedreich's Ataxia. This event will provide insights into the progress and future plans for this therapeutic candidate. Investors will have the opportunity to learn more about the company's strategy for addressing this debilitating disease.
Larimar Therapeutics to host investor event on Monday By Investing.com
Larimar Therapeutics (NASDAQ:LRMR) is hosting an investor event on Monday, June 29, 2026, to discuss updates on its nomlabofusp clinical development program for Friedreich's ataxia, including regulatory information and long-term study data. The clinical-stage biotech company, with a market capitalization of $376 million, is focused on developing treatments for rare diseases, and analysts maintain price targets between $7 and $26. Recent developments also include the election of new Class III directors and increased share count approval, alongside favorable analyst coverage from JPMorgan and Citizens.
Larimar Therapeutics to host investor event on Monday By Investing.com
Larimar Therapeutics (NASDAQ:LRMR) will host an investor event on Monday, June 29, 2026, to provide updates on its nomlabofusp clinical development program for Friedreich’s ataxia, including regulatory information and long-term study data. The clinical-stage biotechnology company, valued at $376 million, is considered potentially undervalued with substantial upside potential by analysts. Recent developments include new board elections and "Overweight" ratings from JPMorgan and Citizens, underscoring ongoing investor interest.
Larimar to discuss Friedreich’s ataxia drug data June 29
Larimar Therapeutics will host an investor webcast on June 29, 2026, at 7:45 a.m. ET to provide updates on its nomlabofusp clinical development program for Friedreich's ataxia. The event will include a regulatory update and data from an ongoing long-term open-label study. Following the news, Larimar's stock (LRMR) saw a positive market reaction, gaining 5.19%.
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia
Larimar Therapeutics will host an investor event on Monday, June 29, 2026, to discuss updates on its nomlabofusp clinical development program for Friedreich's ataxia. The event will include a regulatory update and data from an ongoing long-term open-label study. A webcast will be available for those interested in attending.
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia
Larimar Therapeutics announced an upcoming investor event for Monday, June 29, 2026, to provide updates on its nomlabofusp clinical development program for Friedreich’s ataxia. The event will cover regulatory updates and data from an ongoing long-term open-label study. Larimar Therapeutics, a clinical-stage biotechnology company, is focused on developing treatments for complex rare diseases using its lead compound, nomlabofusp, and its intracellular delivery platform.
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia
Larimar Therapeutics, Inc. (Nasdaq: LRMR) will host an investor event on Monday, June 29, 2026, at 7:45 am ET to provide updates on its nomlabofusp clinical development program for Friedreich’s ataxia. The event will include a regulatory update and data from the ongoing long-term open-label study. A webcast will be available for those who wish to attend virtually.
Larimar To Host Investor Event On Nomlabofusp Program On Monday, Stock Up
Larimar Therapeutics (LRMR) announced an upcoming investor event for Monday, June 29, 2026, to provide updates on its Nomlabofusp program for Friedreich's ataxia. The company will share regulatory updates and data from its Phase 2 study, and also plans to leverage its delivery platform for other rare diseases. The stock saw a significant increase, trading up 4.57% on Friday and an additional 9.29% in after-hours trading.
Larimar Therapeutics, Inc. Actuals & Estimates (NASDAQ:LRMR)
This article provides key financial data and analyst estimates for Larimar Therapeutics, Inc. (NASDAQ:LRMR), including its current stock price, market capitalization, historical performance, and future forecasts. It details information on financial actuals and estimates, revenue, earnings reports, and volatility, along with analyst recommendations.
Larimar Therapeutics Up Nearly 32%, on Pace for Largest Percent Increase Since February 2024 -- Data Talk
Larimar Therapeutics (LRMR) stock surged by nearly 32%, marking its largest percentage increase since February 2024. This significant rise follows the release of positive data from its Phase 2 clinical trial for its lead product candidate, CTLR-02, which is being studied for the treatment of Friedreich's ataxia. The promising clinical trial results have positively impacted investor sentiment and the company's stock performance.
What Just Happened with Larimar Therapeutics (LRMR) and Why Does it Matter
Larimar Therapeutics (LRMR) shares surged over 32% after its lead candidate, nomlabofusp, received FDA Breakthrough Therapy Designation for Friedreich's Ataxia. This designation significantly de-risks the program, validates its potential with positive clinical data for frataxin protein restoration and functional improvements, and accelerates its path to market with a targeted BLA submission in June 2026. Despite potential safety concerns (anaphylaxis observed in some patients), analysts hold a "Buy" rating, anticipating substantial market opportunity in the Friedreich's Ataxia market.
Larimar Therapeutics Inc (LRMR) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Larimar Therapeutics Inc (LRMR) stock information, focusing on its dividend history and stock split events. The company has not distributed any dividends in the past five years. It also details a 12-to-1 merger-based stock split that occurred on May 28, 2020.
Larimar Therapeutics Inc (LRMR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Larimar Therapeutics Inc (LRMR). It notes that relevant data for business segments and regional revenue have not been disclosed by the company yet for FY2019. The article primarily functions as a data placeholder page, stating the lack of available information for the specified categories.
Larimar Therapeutics Inc (LRMR) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Larimar Therapeutics Inc (LRMR), identifying its major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding trends over recent quarters, and recent shareholder activity by key investors. Additionally, it lists several ETFs that include LRMR in their portfolios.
Larimar Therapeutics Inc (LRMR) Institutional Confidence
Larimar Therapeutics Inc (LRMR) has an institutional shareholding score of 7.00, placing it 81st out of 388 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 79.20%, marking a 23.65% decrease quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 1.34 million shares, which represents 1.00% of the shares outstanding.
J.P. Morgan Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $9
J.P. Morgan has initiated coverage on Larimar Therapeutics (LRMR.US) with a Buy rating. The financial institution has set a target price of $9 for the company's stock.
JP Morgan Initiates Coverage of Larimar Therapeutics (LRMR) with Overweight Recommendation
JP Morgan has initiated coverage of Larimar Therapeutics (LRMR) with an "Overweight" rating. This indicates that the firm believes LRMR stock will likely outperform the average return of the stocks that JP Morgan covers over the next 12-18 months.
80,590,392 Common Stock of Larimar Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2026.
80,590,392 shares of Common Stock of Larimar Therapeutics, Inc. (LRMR) are under a lock-up agreement set to expire on May 27, 2026. This lock-up prevents executive officers, directors, and certain security holders from selling or transferring shares for 90 days following February 25, 2026, without the consent of J.P. Morgan Securities LLC and Guggenheim Securities, LLC. This measure is typically put in place to stabilize the stock price after a public offering.
Certain Stock Options of Larimar Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2026.
Certain stock options of Larimar Therapeutics, Inc. are subject to a lock-up agreement that concludes on May 27, 2026. This agreement, spanning 91 days from February 25, 2026, prevents executive officers, directors, and specified security holders from selling or transferring common stock or convertible securities without underwriter consent.
Certain Restricted Stock Units of Larimar Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2026.
Certain Restricted Stock Units of Larimar Therapeutics, Inc. are locked up from February 25, 2026, to May 27, 2026. This 91-day lock-up period prevents executive officers, directors, and other security holders from selling or transferring common stock or convertible securities without underwriter consent. The agreement ensures stability following a public offering.
JPMorgan initiates Larimar Therapeutics stock at Overweight By Investing.com
JPMorgan initiated coverage on Larimar Therapeutics (NASDAQ:LRMR) with an Overweight rating and a $9.00 price target, citing significant upside potential from its current trading price of $3.47. The company's lead asset, nomlabofusp, is a treatment for Friedreich's ataxia, with anticipated topline results and FDA feedback in Q2 2026, and a rolling BLA submission expected in June 2026. Other analysts have also reiterated positive outlooks, with price targets ranging from $12.00 to $26.00, reflecting confidence in the company's regulatory progress and strategic initiatives.
JPMorgan initiates Larimar Therapeutics stock at Overweight
JPMorgan has initiated coverage on Larimar Therapeutics (NASDAQ:LRMR) with an Overweight rating and a $9.00 price target, noting significant upside potential from the current $3.47 stock price. The company's lead asset, nomlabofusp for Friedreich’s ataxia, is expected to have topline results in Q2 2026 and a rolling BLA submission for accelerated approval in June 2026. Other analysts have also reaffirmed positive ratings, contributing to overall confidence in Larimar's strategic initiatives and regulatory progress.
Certain Pre-Funded Warrants of Larimar Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2026.
Certain pre-funded warrants of Larimar Therapeutics, Inc. are subject to a lock-up agreement that ends on May 27, 2026. This agreement restricts executive officers, directors, and certain security holders from selling or transferring common stock or convertible securities for 90 days following February 25, 2026, without the consent of J.P. Morgan Securities LLC and Guggenheim Securities, LLC. The total number of common stock of Larimar Therapeutics, Inc. subject to a lock-up agreement ending on the same date is 80,590,392.
[Form 4] Larimar Therapeutics, Inc. Insider Trading Activity
Larimar Therapeutics (LRMR) reported an insider trading activity in a Form 4 filing. The report details a stock option grant to an entity associated with Deerfield Management, covering 55,150 common shares with an exercise price of $3.33 and an expiration date of May 19, 2036. The options were granted to Jonathan S. Leff, a director of Larimar, and are held for the benefit of Deerfield Management Company, L.P. The options will vest upon Leff's continued board service, either on May 19, 2027, or the date of Larimar's next annual stockholder meeting.
Larimar Therapeutics (LRMR) entity tied to director receives 55,150 stock options
Larimar Therapeutics (LRMR) reported that an entity associated with director Jonathan S. Leff was granted 55,150 stock options with an exercise price of $3.33 per share, expiring on May 19, 2036. Leff, a partner at Deerfield Management Company, L.P., disclaims personal beneficial ownership, holding the options for Deerfield, and they vest subject to his continued service on the board. This transaction represents a neutral filing impact and sentiment, detailing the specifics of the compensatory grant and its terms.
Larimar Therapeutics stockholders approve board elections and share increase
Larimar Therapeutics shareholders approved board elections and an increase in authorized common stock from 115 million to 215 million shares during their 2026 Annual Meeting. Directors Frank Thomas, Carole S. Ben-Maimon, M.D., and Joseph Truitt were re-elected as Class III directors, and PricewaterhouseCoopers LLP was ratified as the independent accounting firm. The company recently completed a $100 million equity offering and its drug candidate, nomlabofusp, received FDA Breakthrough Therapy designation for Friedreich’s ataxia.
Larimar Therapeutics (LRMR) awards 55,150 stock options to director
Larimar Therapeutics director Jeffrey W. Sherman was granted 55,150 stock options with an exercise price of $3.33 per share, expiring on May 19, 2036. This compensation-related award vests on the earlier of May 19, 2027, or the company's next annual stockholder meeting, contingent on his continued board service. This transaction is categorized as an award, not an open-market trade.
Larimar Therapeutics (LRMR) director receives 55,150 stock options grant
Larimar Therapeutics director Joseph Truitt was granted 55,150 stock options with an exercise price of $3.33 per share, expiring on May 19, 2036. These options vest on the earlier of May 19, 2027, or the date of the next annual meeting, contingent on his continued service on the Board of Directors. Following this grant, Truitt directly holds 55,150 stock options.
Larimar Therapeutics (LRMR) director awarded 55,150 stock options at $3.33 strike
Larimar Therapeutics director Frank E. Thomas was granted 55,150 stock options as equity compensation, with an exercise price of $3.33 per share. These options vest on the earlier of May 19, 2027, or the date of the next annual stockholder meeting, contingent on his continued service on the board. This transaction is considered a routine, service-based incentive rather than an open-market trade.
Larimar Therapeutics (LRMR) director gets 55,150 stock options at $3.33 strike
Larimar Therapeutics director Thomas Edward Hamilton was granted 55,150 stock options with an exercise price of $3.33 per share, expiring on May 19, 2036. These options vest on the earlier of May 19, 2027, or the company's next annual stockholder meeting, contingent on his continued service on the board. This transaction is a compensation-related award and not an open-market purchase or sale of common stock.
Larimar Therapeutics stockholders approve board elections and share increase
Larimar Therapeutics (NASDAQ:LRMR) stockholders approved the election of three Class III directors, advisory executive compensation, and ratification of PricewaterhouseCoopers LLP as the accounting firm. Crucially, they also approved an amendment to increase the authorized common stock from 115 million to 215 million shares. The decisions follow a period of significant company activity, including a successful equity offering and Breakthrough Therapy designation for its drug candidate, nomlabofusp.
Larimar Therapeutics (NASDAQ: LRMR) holders back big authorized share increase
Larimar Therapeutics stockholders approved a significant increase in authorized common shares from 115 million to 215 million at their 2026 annual meeting. This move expands the company's capacity for future equity-related actions, although it does not immediately issue new shares. Shareholders also re-elected Class III directors, approved executive compensation, and ratified PricewaterhouseCoopers LLP as the independent auditor for 2026.
Larimar Therapeutics (Nasdaq:LRMR) - Stock Analysis
Larimar Therapeutics (Nasdaq:LRMR) is a clinical-stage biotechnology company focused on developing treatments for rare diseases, particularly Friedreich's ataxia (FA) with its lead candidate nomlabofusp. The stock is currently trading at US$3.57, well below an analyst price target of US$15.88, indicating it is significantly undervalued. Recent news includes FDA Breakthrough Therapy Designation for nomlabofusp and a planned Biologics License Application (BLA) submission for June 2026, alongside several equity offerings and positive long-term study data.
